Seizing Entrepreneurial Opportunities in Pudong: Embracing the Rise of Returnee Entrepreneurs
From November 9th to 11th, under the guidance of the United Front Work Department of the Shanghai Municipal Committee (Overseas Chinese Affairs Office of the Municipal Government), the “Overseas Chinese Innovation and Entrepreneurship Study Camp” (the 3rd Study Camp for Overseas Chinese Young Science and Technology Entrepreneurs and the 16th Study Camp for Overseas Chinese Returnees’ Entrepreneurship) was hosted by the United Front Work Department of the Pudong New Area Committee (Overseas Chinese Affairs Office of the District Government) and commenced in Zhangjiang. Focusing on the trend of overseas talent “returning” to China, the event aims to provide a platform for nurturing and fostering the innovation and entrepreneurship of young people in the overseas Chinese community who come to Shanghai, further strengthen exchanges with the new generation of overseas Chinese, and cultivate their patriotism and love for their hometown.
Meanwhile, Shanghai Television’s program “632 Observations” also conducted an interview with Kayla Yuan, a director at HB Ventures, to explore together the new opportunities being discovered by young overseas Chinese science and technology entrepreneurs.
Related Posts
” E-Tronic(Guangzhou) Technology” completes Series A financing led by Infinity Capital
E-Tronic(Guangzhou)Technology Co.，Ltd., a provider of power semiconductors and system solutions for new energy vehicles, has completed its Series A financing with a cumulative amount of over 100 million RMB. This round of financing was led by Infinity Capital, with additional investment from old shareholders Zhongnan Venture Capital and Guangzhou Development
Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare
NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences. According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer
FDA Approves IND for LAE120, a Novel USP1 Inhibitor for Advanced Solid Tumors (March 4, 2025)
In March 2025, Laekna announced that the FDA approved the IND for LAE120, a novel USP1 inhibitor developed internally for advanced solid tumors. LAE120 shows potent monotherapy anti-tumor activity and synergy with PARP inhibitors, especially in homologous recombination deficiency (HRD) cancers. It demonstrated strong tumor inhibition in various xenograft models
MDHC Technologies Secures Series B Funding to Accelerate Growth and Innovation (2024)
MDHC Technologies completed a Series B funding round with investors including Chery Automobile, LAKSIMI Capital, Lucion Venture Capital Group, Yongxin Fangzhou, Addor Capital, and others. The funding will accelerate the development of its intelligent manufacturing platform, expand production capacity, and increase R&D investment, driving innovation and mark